Protagonist Therapeutics (PTGX) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 11/06/25
Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateAccesswire • 11/06/25
Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH MeetingAccesswire • 11/03/25
Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 10/30/25
Protagonist Therapeutics Stock Gains 30% as J&J Reportedly Eyes DealZacks Investment Research • 10/13/25
Protagonist Therapeutics, Inc. (PTGX) Presents At H.C. Wainwright 27th Annual Global Investment Conference TranscriptSeeking Alpha • 09/11/25
Protagonist Therapeutics, Inc. (PTGX) Presents At Citi's Biopharma Back To School Conference TranscriptSeeking Alpha • 09/03/25
Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025Accesswire • 08/26/25
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/06/25
Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAccesswire • 08/06/25
Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?Investors Business Daily • 06/30/25
Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development CandidateAccesswire • 06/26/25
Protagonist Therapeutics: Two 'Slam Dunk' Sets Of Pivotal Data Set Up Bull CaseSeeking Alpha • 06/20/25
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia VeraBusiness Wire • 06/01/25
Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025Accesswire • 05/21/25
Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/06/25
Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate UpdateAccesswire • 05/06/25
Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025Accesswire • 04/23/25